MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator (Q40735560)

23 September 2017

title

MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator (English)

1 reference

Catherine Alcaide-Loridan

23 September 2017

author

11

object named as

Catherine Alcaïde-Loridan

0 references

author name string

Rodrigo Naves

1

1 reference

23 September 2017

Ana Maria Lennon

2

1 reference

23 September 2017

Giovanna Barbieri

3

1 reference

23 September 2017

Lilian Reyes

4

1 reference

23 September 2017

Gisella Puga

5

1 reference

23 September 2017

Laura Salas

6

1 reference

23 September 2017

Virginie Deffrennes

7

1 reference

23 September 2017

Mario Rosemblatt

8

1 reference

23 September 2017

Marc Fellous

9

1 reference

23 September 2017

Dominique Charron

10

1 reference

23 September 2017

Maria Rosa Bono

12

1 reference

23 September 2017

publication date

1 May 2002

1 reference

23 September 2017

published in

International Immunology

1 reference

23 September 2017

volume

14

1 reference

23 September 2017

issue

5

1 reference

23 September 2017

page(s)

481-491

1 reference

MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Sequences and factors: a guide to MHC class-II transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

The molecular basis of MHC class II deficiency and transcriptional control of MHC class II gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Class II-antigen-negative patient and mutant B-cell lines represent at least three, and probably four, distinct genetic defects defined by complementation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Class II transactivator: mastering the art of major histocompatibility complex expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Isolation of a B-cell-specific promoter for the human class II transactivator

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Natural history of HLA expression during tumour development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Human chromosome 16 encodes a factor involved in induction of class II major histocompatibility antigens by interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Characterization of human IFN-gamma response using somatic cell hybrids of hematopoietic and nonhematopoietic origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Chromosome 11q localization of one of the three expected genes for the human alpha-3-fucosyltransferases, by somatic hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

High-efficiency transformation of mammalian cells by plasmid DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

The recombinant human interferon-γ receptor is fully functional in a human × murine hybrid containing human chromosome 21

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Genetic analysis of mammalian cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Methylation of class II trans-activator promoter IV: a novel mechanism of MHC class II gene control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

CD4 T cells and their role in antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Cutting edge: the class II transactivator prevents activation-induced cell death by inhibiting Fas ligand gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Combinations of dominant-negative class II transactivator, p300 or CDK9 proteins block the expression of MHC II genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

Mouse class II transactivator: cDNA sequence and amino acid comparison with the human class II transactivator

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2F14.5.481

21 January 2018

Identifiers

DOI

10.1093/INTIMM/14.5.481

1 reference

23 September 2017

1 reference